Search: onr:"swepub:oai:prod.swepub.kib.ki.se:146047092" > Standardized monito...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04010naa a2200601 4500 | |
001 | oai:prod.swepub.kib.ki.se:146047092 | |
003 | SwePub | |
008 | 240902s2021 | |||||||||||000 ||eng| | |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1460470922 URI |
024 | 7 | a https://doi.org/10.3324/haematol.2019.2292522 DOI |
040 | a (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Wagner-Drouet, E4 aut |
245 | 1 0 | a Standardized monitoring of cytomegalovirus-specific immunity can improve risk stratification of recurrent cytomegalovirus reactivation after hematopoietic stem cell transplantation |
264 | c 2019-12-26 | |
264 | 1 | b Ferrata Storti Foundation (Haematologica),c 2021 |
520 | a Recurrence of cytomegalovirus reactivation remains a major cause of morbidity and mortality following allogeneic hematopoietic stem cell transplantation. Monitoring cytomegalovirus-specific cellular immunity using a standardized assay might improve the risk stratification of patients. A prospective multicenter study was conducted in 175 intermediate- and high-risk allogeneic hematopoietic stem cell transplant recipients under preemptive antiviral therapy. Cytomegalovirus-specific cellular immunity was measured using a standardized IFN-γ ELISpot assay (T-Track® CMV). Primary aim was to evaluate the suitability of measuring cytomegalovirus-specific immunity after end of treatment for a first cytomegalovirus reactivation to predict recurrent reactivation. 40/101 (39.6%) patients with a first cytomegalovirus reactivation experienced recurrent reactivations, mainly in the high-risk group (cytomegalovirus-seronegative donor/cytomegalovirus-seropositive recipient). The positive predictive value of T-Track® CMV (patients with a negative test after the first reactivation experienced at least one recurrent reactivation) was 84.2% in high-risk patients. Kaplan-Meier analysis revealed a higher probability of recurrent cytomegalovirus reactivation in high-risk patients with a negative test after the first reactivation (hazard ratio 2.73; p=0.007). Interestingly, a post-hoc analysis considering T-Track® CMV measurements at day 100 post-transplantation, a time point highly relevant for outpatient care, showed a positive predictive value of 90.0% in high-risk patients. Our results indicate that standardized cytomegalovirus-specific cellular immunity monitoring may allow improved risk stratification and management of recurrent cytomegalovirus reactivation after hematopoietic stem cell transplantation. This study was registered at www.clinicaltrials.gov as #NCT02156479. | |
700 | 1 | a Teschner, D4 aut |
700 | 1 | a Wolschke, C4 aut |
700 | 1 | a Janson, D4 aut |
700 | 1 | a Schafer-Eckart, K4 aut |
700 | 1 | a Gartner, J4 aut |
700 | 1 | a Mielke, Su Karolinska Institutet4 aut |
700 | 1 | a Schreder, M4 aut |
700 | 1 | a Kobbe, G4 aut |
700 | 1 | a Kondakci, M4 aut |
700 | 1 | a Hilgendorf, I4 aut |
700 | 1 | a von Lilienfeld-Toal, M4 aut |
700 | 1 | a Klein, S4 aut |
700 | 1 | a Heidenreich, D4 aut |
700 | 1 | a Kreil, S4 aut |
700 | 1 | a Verbeek, M4 aut |
700 | 1 | a Grass, S4 aut |
700 | 1 | a Ditschkowski, M4 aut |
700 | 1 | a Gromke, T4 aut |
700 | 1 | a Koch, M4 aut |
700 | 1 | a Lindemann, M4 aut |
700 | 1 | a Hunig, T4 aut |
700 | 1 | a Schmidt, T4 aut |
700 | 1 | a Rascle, A4 aut |
700 | 1 | a Guldan, H4 aut |
700 | 1 | a Barabas, S4 aut |
700 | 1 | a Deml, L4 aut |
700 | 1 | a Wagner, R4 aut |
700 | 1 | a Wolff, D4 aut |
710 | 2 | a Karolinska Institutet4 org |
773 | 0 | t Haematologicad : Ferrata Storti Foundation (Haematologica)g 106:2, s. 363-374q 106:2<363-374x 1592-8721x 0390-6078 |
856 | 4 | u https://haematologica.org/article/download/9588/70385 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:146047092 |
856 | 4 8 | u https://doi.org/10.3324/haematol.2019.229252 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.